New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Deb Mills

Dr Deb Mills

Travel Medicine Update for General Practice

Dr Katherine Spira

Dr Katherine Spira

Choosing the Right Migraine Preventative

Dr Jay Ramanathan, A/Prof David Sullivan, facilitated by A/Prof Ralph Audehm

Dr Jay Ramanathan, A/Prof David Sullivan, facilitated by A/Prof Ralph Audehm

Expert Panel – Atherosclerosis and Blood Lipid Management

A/Prof Daryl Efron

A/Prof Daryl Efron

Autism – When & Who to Refer

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023